Beyond these mechanistic insights, determining whether ACC’s dependency on MMP-14 represents a general feature of aggressive cancers or a tumor type-specific vulnerability will be essential for predicting which patients are most likely to benefit from MMP-14-targeted therapies. Here, MMP14 is linked to adrenal cortex carcinoma.